Abstract 2532: integrated therapeutic antibody development at the National Research Council of Canada

Download
  1. Get@NRC: Abstract 2532: integrated therapeutic antibody development at the National Research Council of Canada (Opens in a new window)
DOIResolve DOI: http://doi.org/10.1158/1538-7445.AM2012-2532
AuthorSearch for: ; Search for:
TypeArticle
Journal titleCancer Research
ISSN0008-5472
1538-7445
Volume72
Issue8 Supplement
Pages25322532
AbstractAdvances in genomics and antibody engineering have enabled the development of an innovative class of targeted therapies to provide new treatment options for diseases with significant unmet medical needs such as cancer. Therapeutic antibodies represent one of the fastest growing classes of medications with sales anticipated to exceed $30 billion globally by 2012. The NRC has built a chain of cutting edge technology platforms needed to discover, engineer and produce therapeutic monoclonal antibodies with the goal of partnering with industrial and academic centers to advance research and development of this important class of therapeutics. Target Identification- To establish and validate the technology platform, tumor targets for candidate therapeutic antibody production were identified using a combination of proteomics, transcriptomics and bioinformatic approaches. Out of these lists, approximately 40 tumor targets were selected (known therapeutic antibody targets were excluded), and over 2,000 antibodies of mouse and camelid origin were then generated against these targets. Antibody generation- Once identified, the recombinant target protein of interest can be produced using the NRC's high efficiency cell expression platforms in CHO or HEK293 cells and purified protein used for immunization or panning. For targets which are difficult to express or purify, the capabilities for direct immunization with plasmid DNA constructs provides another option. Clone selection is carried out by ELISA and typically 50 antibodies/target are identified for further characterization. Antibody characterization and validation- The affinities of the antibodies are determined by SPR biosensor analysis. Reverse phase protein arrays and Western blot analysis on protein mixes and cell lines allow the characterization of the specificity of the antibodies. Epitope mapping can be carried out so that representative antibodies from each epitope bin can be selected for further validation in appropriate cell-based assays (many of which are established at NRC) and animal models. Therapeutic antibody Optimization, Bioprocessing and Biomanufacturing- Therapeutic antibodies selected for development can be further optimized using antibody engineering technologies to humanize them and/or modify their glycosylation patterns to improve their effector function, pharmacokinetics, solubility and stability as well as reduce their immunogenicity. The NRC platform for large scale protein production has the capacity to manufacture up to 13.5 g of commercial grade antibody using serum free, low endotoxin media in a cGMP certified CHO cell line which is ready for transfer to CMOs or other industrial partners.
Publication date
PublisherAmerican Association for Cancer Research
LanguageEnglish
AffiliationHuman Health Therapeutics; National Research Council Canada
Peer reviewedYes
NPARC number23001785
Export citationExport as RIS
Report a correctionReport a correction
Record identifier43e3adb3-7a37-4997-8810-9a01dd13295c
Record created2017-04-06
Record modified2017-04-06
Bookmark and share
  • Share this page with Facebook (Opens in a new window)
  • Share this page with Twitter (Opens in a new window)
  • Share this page with Google+ (Opens in a new window)
  • Share this page with Delicious (Opens in a new window)